What is Cbset?
Operating as a not-for-profit entity, Cbset functions as a high-tier research hub that integrates in vivo and in vitro studies with advanced computational modeling. The company maintains a 40,000-square-foot facility that is both OLAW-assured and AAALAC-accredited, providing a comprehensive suite of services ranging from catheterization and imaging labs to complex histopathology. By bridging the gap between academic research and commercial regulatory requirements, Cbset has established itself as an essential partner for sponsors aiming to navigate the complexities of biomedical development. Their integrated paradigm allows for a seamless transition from initial scientific inquiry to final regulatory submission, ensuring that sponsors meet their commercial objectives with precision and technical rigor.
How much funding has Cbset raised?
Cbset has raised a total of $2.2M across 2 funding rounds:
Debt
$1M
Debt
$1.2M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.2M led by PPP
Key Investors in Cbset
PPP
Public-Private Partnership
What's next for Cbset?
With the recent capital infusion, Cbset is well-positioned to expand its technical and scientific acumen, further solidifying its footprint in the competitive preclinical research landscape. The strategic allocation of these funds will likely focus on enhancing the institute's existing infrastructure, including its specialized imaging and surgical suites, to accommodate increasingly complex collaborative projects. As the medical device and pharmaceutical industries continue to demand higher standards of data integrity and regulatory compliance, Cbset's commitment to high-quality, integrated research services will remain a primary driver of its long-term growth trajectory. The institute is expected to leverage this financial backing to deepen its partnerships within the academic and commercial communities, ultimately accelerating the pace of biomedical innovation.
See full Cbset company page
